| Trial ID: | L2254 |
| Source ID: | NCT02639130
|
| Associated Drug: |
Exendin [9-39]
|
| Title: |
GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Exendin [9-39]|DRUG: Placebo
|
| Outcome Measures: |
Primary: Ratio of integrated insulin secretion rates (total AUC ISR) over 4 hour following the meal, 4 hour following the meal|total AUC Glucose over 4 hour following the meal, 4 hour following the meal |
|
| Sponsor/Collaborators: |
Sponsor: Diabeteszentrum Bad Lauterberg im Harz
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
67
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-02
|
| Completion Date: |
2010-01
|
| Results First Posted: |
|
| Last Update Posted: |
2016-08-16
|
| Locations: |
Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Niedersachsen, 37431, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT02639130
|
